Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 5Tumor-Agnostic 2Other solid neoplasm 1

Conditions

Neoplasms 2

Interventions

pembrolizumab 46Paclitaxel 46Gemcitabine 41Carboplatin 37Docetaxel 35Bevacizumab 27Cisplatin 25Irinotecan 22Nivolumab 20Fluorouracil 20Erlotinib Hydrochloride 18Pemetrexed 17Capecitabine 17Sorafenib 16Magnetic Resonance Spectroscopy 16Cetuximab 16Afatinib 16Leucovorin 15regorafenib 14olaparib 13Specimen Handling 13Oxaliplatin 13trametinib 12Biopsy 12130-nm albumin-bound paclitaxel 11eribulin 10atezolizumab 10epothilone B 9Radiotherapy 9Midazolam 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × necitumumab × Tumor-Agnostic × Clear all
NCT01088464 2017-02-03

Study of IMC-11F8 in Participants With Advanced Solid Tumors

Eli Lilly and Company

Phase 1 Completed
15 enrolled 22 charts
Tumor-Agnostic

Neoplasms

NCT00801177 2010-10-13

Study of IMC-11F8 in Patients With Tumors Who Have Not Responded to Standard Therapy

Eli Lilly and Company

Phase 1 Completed
60 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡